Zacks Investment Research on MSN
PMVP stock rises 19% in 3 months: Here's what you need to know
PMV Pharmaceuticals PMVP has gained nearly 19% in the past three months, primarily due to encouraging clinical data for its ...
PMV Pharmaceuticals is rated Buy, targeting $3–$4/share, driven by Rezatapopt's 46% response rate. Click to read more about ...
Dr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets at Samsara BioCapital, ...
PMV Pharmaceuticals Inc. (NASDAQ:PMVP) on Monday shared interim data from its Phase 2 PYNNACLE trial for rezatapopt, an investigational treatment for ovarian cancer.Based on this data, the company ...
The tumor-suppressing protein p53 has long been considered a valuable target—if only drug hunters could figure out how to hit it. Many research efforts aiming to leverage the capabilities of this ...
The filing reveals that Dr. Matthew Eckler joined the board of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) PMVP (NASDAQ:PMVP) on ...
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results